Moderna. has filed a patent for modified nucleosides, nucleotides, and nucleic acids for use in synthetic messenger ribonucleic acid (mRNA) production. The method involves selecting nucleotides that disrupt binding with major groove binding partners, resulting in mRNA synthesis encoding pharmaceutical proteins. GlobalData’s report on Moderna gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Moderna, mRNA delivery lipid nanoparticles was a key innovation area identified from patents. Moderna's grant share as of January 2024 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
Modified mrna for pharmaceutical protein synthesis with improved binding
The patent application (Publication Number: US20240033379A1) discloses a method for synthesizing a synthetic messenger ribonucleic acid (mRNA) for pharmaceutical purposes. The method involves providing a complementary deoxyribonucleic acid (cDNA) encoding a pharmaceutical protein, selecting a nucleotide that disrupts the binding of major groove binding partners with the RNA, and synthesizing the mRNA transcript using an RNA polymerase. The mRNA is then capped at the 5' end to complete the synthesis process. The nucleotide used in the process contains modifications on the major groove face of the nucleobase to reduce binding affinity to major groove binding partners such as toll-like receptors and other proteins involved in immune response.
Furthermore, the patent application includes claims related to the length of the mRNA, specific modifications on the nucleotide, and the major groove binding partners targeted in the synthesis process. Additionally, the application describes methods for synthesizing pharmaceutical nucleic acids and formulating pharmaceutical compositions using the synthetic mRNA. The invention also covers methods for producing pharmaceutical formulations containing physiologically active secreted proteins by transfecting human cells with the synthetic mRNA. Overall, the patent application outlines a novel approach to synthesizing mRNA for pharmaceutical applications, focusing on enhancing the efficacy and specificity of the mRNA through nucleotide modifications and targeting specific binding partners in the major groove of the nucleobase.
To know more about GlobalData’s detailed insights on Moderna, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
